Ramachandran Murali

Professor

Cedars-Sinai Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Year:

2026

ARF GTPase protein 1 (GIT1) is a scaffold protein that is overexpressed in hepatocellular carcinoma (HCC) and colorectal cancer (CRC). GIT1 forms a complex with methionine adenosyltransferase 2B (MAT2B) that activates RAS-RAF-MEK-ERK signaling in HCC and CRC to enhance tumorigenicity. Here, we investigated in a proof-of-concept study whether a small molecule that disrupts GIT1-MAT2B interaction can be effective in HCC and CRC treatment. Since the GIT1 crystal structure is unavailable, we developed a molecular model and used computer-based drug discovery approach to screen for small molecules targeting the GIT1 ankyrin repeat domain, the region closest to where MAT2B interacts that is accessible. Of nine compounds tested, compound 3 (C3) selectively interacts with GIT1 and shows an anti-cancer effect in a GIT1-dependent manner. C3 is antiproliferative, induced apoptosis and G2/M cell cycle arrest while inhibiting colony formation and migration in liver and colon cancer cells. C3 lowered interaction between GIT1 and MAT2B, and with downstream effectors cRAF, MEK and ERK, lowering MEK activity and cyclin D1 expression. Unexpectedly, C3 stabilized GIT1 interaction with cyclin B1 while weakening cyclin B1’s interaction with components of the anaphase promoting complex, concomitant with sustained cyclin B1 expression and mitosis arrest. In mice, C3 administration was well tolerated and inhibited murine CRC growth and liver metastasis in immune competent mice and human CRC growth in the livers of nude mice. In conclusion, a small molecule inhibitor that disrupts GIT1’s normal interactome is a promising new approach to treating liver and colon cancers.

Year:

2026

Year:

2026

Year:

2026

The CUT/Hox transcription factor ONECUT2 (OC2) promotes lineage plasticity and is a confirmed therapeutic target in prostate cancer and several other malignancies where cell phenotype plays a substantial role in treatment resistance. OC2 governs a broad growth and lineage identity process in prostate cancer that promotes neuroendocrine (NE) differentiation, androgen receptor (AR) suppression, and the emergence of a wide range of treatment-resistant pathways. The mode of action of OC2 includes incorporation of the protein into transcription complexes at gene promoters as an activator and repressor, alteration of chromatin accessibility and epigenetic marks, and extensive alteration of large-scale chromatin modifications, such as super-enhancers and chromatin loops. Notably, OC2 may be unique among NE drivers in that it can promote AR indifference in adenocarcinoma as a direct upstream activator of the glucocorticoid receptor, thus assuming indirect control of a portion of the AR cistrome. OC2 expression and activity increase substantially following hormone therapy in association with aggressive disease in prostate and breast cancer. Experiments in model systems have shown that OC2 has a survival function in both human castration-sensitive and castration-resistant prostate cancer cells. OC2 can be targeted directly with a family of novel small-molecule inhibitors that show therapeutic efficacy in vivo in prostate, breast, and gastric cancer models, including regression of established distant metastases in mice. These findings suggest that inhibition of OC2 clinically may confer substantial therapeutic benefit in some aggressive malignancies, including in localized hormone-sensitive disease.

Year:

2025

Despite wide applications of CRISPR/Cas9 technology, effective approaches for CRISPR delivery with functional control are limited. In an attempt to develop a nanoscale CRSIPR/Cas9 delivery platform, we discovered that several biocompatible polymers, including polymalic acid (PMLA), polyglutamic acid (PGA), and polyaspartic acid (PLD), when conjugated with a trileucine (LLL) moiety, can effectively inhibit Cas9 nuclease function. The Cas9 inhibition by those polymers is dose-dependent, with varying efficiency to achieve 100% inhibition. Further biophysical studies revealed that PMLA-LLL directly binds the Cas9 protein, resulting in a substantial decrease in Cas9/sgRNA binding affinity. Transmission electron microscopy and molecular docking were performed to provide a possible binding mechanism for PMLA-LLL to interact with Cas9. This work identified a new class of Cas9 inhibitor in nano-polymer form. These biodegradable polymers may serve as novel Cas9 delivery vehicles with a potential to enhance the precision of Cas9-mediated gene editing.

Year:

2025

Glucocorticoid-induced Tumor Necrosis Factor Receptor (GITR) and its ligand GITRL, members of the TNFR superfamily, play critical roles in T cell activation and modulation. GITR is expressed on activated T cells and Tregs, while GITRL is found on APCs, including dendritic cells and macrophages. GITR-GITRL interaction induces trimerization, essential for signaling and T cell activation. In humans, trimerization enhances T cell proliferation and suppresses Tregs. However, clinical trials with GITR agonist antibodies in humans have shown limited efficacy, likely due to insufficient GITRL trimerization. To address this, we analyzed soluble human GITRL and found an equilibrium between dimers and trimers. We developed KROS 101, a novel small molecule GITR agonist, to stabilize GITRL trimerization and enhance signaling. Surface plasmon resonance assays confirmed high-affinity binding of KROS 101 to hGITRL. Functional assays demonstrated that KROS 101 significantly increased CD3+ T cell proliferation, particularly CD4+ and CD8+ subsets, while suppressing Tregs. Treated T cells exhibited enhanced cytotoxicity against glioblastoma (GBM) cell lines and patient-derived glioma cancer stem cells (CSCs), showing superior anti-tumor activity compared to controls. To evaluate in vivo effects, we used a humanized GITR/GITRL double knock-in mouse model. In a melanoma model (B16-F10-Luc2), KROS 101 significantly inhibited tumor growth, with reduced luminescence intensity and smaller tumors compared to those treated with the clinical-stage GITR antibody TRX518. Immune profiling revealed increased CD3+ and CD8+ T cell infiltration and reduced Tregs within the tumor microenvironment (TME). KROS 101 also enhanced effector T cell populations, shifting the TME towards an effective anti-tumor response. These effects surpassed those observed with TRX518. In summary, KROS 101 is a potent GITR agonist that promotes T cell infiltration, proliferation, and cytotoxicity while reducing Treg-mediated suppression. These findings support further development of KROS 101 for clinical trials in cancer immunotherapy, particularly for melanoma and glioblastoma.

Year:

2025

Year:

2025

2587 Background: A small molecule was identified that stabilizes the trimerization of the glucacorticoid-induced tumor necrosis factor receptor (GITR) ligand which then leads to the trimerization of GITR and magnified signaling of GITR. GITR signaling of T cells results in T effector cell expansion and T reg reduction. An antagonist to the GITR ligand was also indentified which stabilizes the GITR ligand dimer formation preventing trimerization. Methods: Binding of KROS 101 to the GITR ligand was assessed and the binding region of GITR ligand to KROS was determined with targeted deletion of GITR. T cell suppression studies were performed with T cell proliferation assays and T cell cytotoxicity assays with glioblastoma target cells using patient derived PBMCs. Double humanized GITR/GITRL mice bearing B16-F10-LUC2 tumors were treated with KROS 101 or controls. Tumor-infiltrating lymphocytes were analyzed by flow cytometry and tumors assessed. Results: KROS 101 agonist binds to GITRL with high affinity with a K D of 340nM by Surface Plasmon resonance. T cell suppression assay showed KROS 101 had peak proliferative induction of T effector cells at 25 uM concentration to 52% increase in proliferation, and peak proliferation induction of T effector cells with 1:1 ratio of T reg cells at 50uM concentration to 80% increase in proliferation of T effectors. KROS 101 treated T cell show enhanced effetor function and selectively target glioblastoma and cancer stem cells in vitro. KROS 101 enhances tumor immune infiltration by Increasing CD3+ T Cells, CD8+ T Cells, and M1 Macrophages While Reducing Tregs and Myeloid Cells in vivo. KROS 101 enhances cytotoxicity by increasing IFNγ and TNFα While Reducing TIGIT and TIM3 in CD4+ and CD8+ T Cells I n Vivo . Conclusions: KROS 101 is a GITR ligand agonist that increases T cell proliferation and increased cytotoxicity and reduces the T reg population more effectively than TRX 518 which is a therapeutic GITR antibody that was in clinical trial.

Year:

2025

Glioblastoma (GBM) is the most aggressive primary brain tumor, with a five-year survival rate of only 5-7%. Current therapies include surgery, chemotherapy, and radiation, but there is an urgent need for alternative strategies to reduce the side effects of these treatments. The paradigm of cancer treatment is shifting toward immunotherapy, which offers tumor target specificity through mechanisms that target specific antigen and receptors. Macrophages play a major role in innate immune system, primarily through phagocytosis and the destruction of harmful organisms. In cancer, they comprise the highest cell concentration among immune cells in the tumor microenvironment (TME). However, most of these macrophages possess pro-tumoral and immunosuppressive (M2-like) phenotype which promotes angiogenesis, tumor invasion and aid in metastasis. Tumor associated macrophages (TAMs) represent the predominant infiltrating immune cell population in gliomas, accounting for 30–50% of the total tumor cell population, and are associated with poor prognosis and higher tumor grades. M1-like TAMs produce proinflammatory cytokines that inhibit tumor progression whereas M2-like TAMs contribute to an immunosuppressive microenvironment, facilitating tumor growth. Hence, inhibition of M2 polarization could be a promising strategy to create a proinflammatory state (M1). We developed a peptide inhibitor, KROS-401, targeting the shared IL-4Ra subunit of the IL-4 and IL-13 receptor complex, aiming to inhibit macrophage polarization to the M2 phenotype and reprogram the immunosuppressive TME. Initially, we derived and differentiated macrophages from human peripheral blood mononuclear cell (PBMC) and characterized for M2 surface markers. These differentiated macrophages demonstrated excellent phagocytotic activity using red zymosan. Subsequently we assessed the effect of KROS-401 on M2 macrophage polarization. Our preliminary results showed decrease in the M2 macrophage population in a dose-dependent manner in the presence of IL-4 and IL-13. Furthermore, our in vivo studies indicated that KROS-401 had an anti-tumor effect in glioma bearing mice, with treated mice showed significantly extended overall survival compared to control group. It is reported that iron oxide nanoparticles can skew macrophages towards the M1 phenotype but no studies have explored their potential for reprogramming macrophages in glioblastoma treatment. To enhance the efficacy of KROS-401 and further reprogram the macrophage/microglia population, we developed an iron oxide nanoparticle conjugated to KROS-401. Preliminary in vitro and in vivo studies shows that the iron oxide nanoparticle conjugated to KROS-401 is safe and may effectively reprogram macrophages to inhibit tumor growth. Citation Format: Dnyaneshwar Kalyane, John Yu, Tesfahun Admasu, Michelot Michel, Hongqiang Wang, Ramachandran Murali. Targeting M2 macrophage polarization: The anti-tumor effects of IL-4/IL-13 blocking peptide (KROS-401) and iron oxide nanoparticles [abstract]. In: Proceedings of the AACR IO Conference: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2025 Feb 23-26; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(2 Suppl):Abstract nr A048.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (15)

Eugenio Cingolani

Associate Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Wei Yang

Associate Professor

Stony Brook University

UNITED STATES
View details

Kai Li

Assistant Professor

University of Connecticut Health Center

UNITED STATES
View details

Avradip Chatterjee

Assistant Professor

The University of Texas Rio Grande Valley

UNITED STATES
View details

Michael Freeman

Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Mirja Rotinen

Public University of Navarre

SPAIN
View details

Michifumi Yamashita

Associate Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Ruan Zhang

Assistant Professor

NYU Langone Health

UNITED STATES
View details

Chuling Zhuang

Baylor College of Medicine

UNITED STATES
View details

Michitaka Matsuda

Senior Researcher

National Center For Global Health and Medicine

JAPAN
View details

Keith Black

Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Edwin Posadas

Associate Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Maria Lauda Tomasi

Cedars-Sinai Medical Center

UNITED STATES
View details

Eduardo Marban

Professor in Residence

University of California, Los Angeles

UNITED STATES
View details

Sungyong You

Professor

Cedars-Sinai Medical Center

UNITED STATES
View details